SCHEMBL2800410

SCHEMBL2800410

O=C(O)c1cnn2c(NCc3ccccc3)c(C(=O)N3CCN(c4ccc(F)cc4)CC3)cnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
SMN1; SMN2 Q16637 3/20 0.50
MAPK1 P28482 2/20 0.50
USP2 O75604 1/20 0.50
MAPT P10636 7/20 0.48
RUVBL1 Q9Y265 1/20 0.46
GFER P55789 3/20 0.45
KDM4E B2RXH2 3/20 0.45
GAA P10253 2/20 0.45
ALOX15 P16050 2/20 0.45
ALOX12 P18054 2/20 0.45
GRM5 P41594 1/20 0.45
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2801231 0.91 TP53 (0.53) TP53MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL2801827 0.90 TP53 (0.48) TP53MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL2800838 0.86 CHRM4 (0.43) TP53MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL2801058 0.84 POLB (0.48) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL2801342 0.83 KDM4E (0.46) TP53KDM4EGAACYP2C9CYP2C19
SCHEMBL2802782 0.81 SRC (0.38) KDM4EALDH1A1SLC6A7
SCHEMBL2800936 0.81 STAT6 (0.42) ALDH1A1SLC6A7
SCHEMBL2800901 0.81 CHRM4 (0.43) TP53MAPTCYP2C9CYP2C19NPSR1
SCHEMBL2800863 0.79 EPHX2 (0.42) SMN1; SMN2KDM4ESLC6A7
SCHEMBL2800791 0.79 ALDH1A1 (0.44) TP53MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 TP53 241/4885MEN1 3065/4885KMT2A 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.